
A Growing Backlog Of Biotechs Haven’t Raised Funding Since The Boom
More than 200 private U.S. biotechs with $50 million or more in funding to date secured their last reported financing between three and five years ...

Why Raising Too Much Funding Is Often Fatal
Too much of a good thing — in this case early-stage funding — can affect founders and their startups in a negative way, writes guest author Dan Gra...

The Week’s 10 Biggest Funding Rounds: AI On Top Again, Led By xAI’s Massive Raise
The pace of large U.S. startup financing announcements was somewhat muted in a shortened Fourth of July workweek. There was, however, one big excep...